Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study.
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
12
04
2024
accepted:
08
08
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
21
8
2024
Statut:
epublish
Résumé
Factors to accurately stratify patients with early-stage non-small cell lung cancer (NSCLC) in different prognostic groups are still needed. This study aims to investigate 1) the prognostic potential of circulating cell-free (CF) and extracellular vesicles (EVs)-derived microRNA (miRNAs), and 2) their added value with respect to known prognostic factors (PFs). The RESTING study is a multicentre prospective observational cohort study on resected stage IA-IIIA patients with NSCLC. The primary end-point was disease-free survival (DFS), and the main analyses were carried out separately for CF- and EV-miRNAs. CF- and EV-miRNAs were isolated from plasma, and miRNA-specific libraries were prepared and sequenced. To reach the study aims, three statistical models were specified: one using the miRNA data only (Model 1); one using both miRNAs and known PFs (age, gender, and pathological stage) (Model 2), and one using the PFs alone (Model 3). Five-fold cross-validation (CV) was used to assess the predictive performance of each. Standard Cox regression and elastic net regularized Cox regression were used. A total of 222 patients were enrolled. The median follow-up time was 26.3 (95% CI 25.4-27.6) months. From Model 1, three CF-miRNAs and 21 EV-miRNAs were associated with DFS. In Model 2, two CF-miRNAs (miR-29c-3p and miR-877-3p) and five EV-miRNAs (miR-181a-2-3p, miR-182-5p, miR-192-5p, miR-532-3p and miR-589-5p) remained associated with DFS. From pathway enrichment analysis, TGF-beta and NOTCH were the most involved pathways. This study identified promising prognostic CF- and EV-miRNAs that could be used as a non-invasive, cost-effective tool to aid clinical decision-making. However, further evaluation of the obtained miRNAs in an external cohort of patients is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Factors to accurately stratify patients with early-stage non-small cell lung cancer (NSCLC) in different prognostic groups are still needed. This study aims to investigate 1) the prognostic potential of circulating cell-free (CF) and extracellular vesicles (EVs)-derived microRNA (miRNAs), and 2) their added value with respect to known prognostic factors (PFs).
METHODS
METHODS
The RESTING study is a multicentre prospective observational cohort study on resected stage IA-IIIA patients with NSCLC. The primary end-point was disease-free survival (DFS), and the main analyses were carried out separately for CF- and EV-miRNAs. CF- and EV-miRNAs were isolated from plasma, and miRNA-specific libraries were prepared and sequenced. To reach the study aims, three statistical models were specified: one using the miRNA data only (Model 1); one using both miRNAs and known PFs (age, gender, and pathological stage) (Model 2), and one using the PFs alone (Model 3). Five-fold cross-validation (CV) was used to assess the predictive performance of each. Standard Cox regression and elastic net regularized Cox regression were used.
RESULTS
RESULTS
A total of 222 patients were enrolled. The median follow-up time was 26.3 (95% CI 25.4-27.6) months. From Model 1, three CF-miRNAs and 21 EV-miRNAs were associated with DFS. In Model 2, two CF-miRNAs (miR-29c-3p and miR-877-3p) and five EV-miRNAs (miR-181a-2-3p, miR-182-5p, miR-192-5p, miR-532-3p and miR-589-5p) remained associated with DFS. From pathway enrichment analysis, TGF-beta and NOTCH were the most involved pathways.
CONCLUSION
CONCLUSIONS
This study identified promising prognostic CF- and EV-miRNAs that could be used as a non-invasive, cost-effective tool to aid clinical decision-making. However, further evaluation of the obtained miRNAs in an external cohort of patients is warranted.
Identifiants
pubmed: 39169404
doi: 10.1186/s13046-024-03156-y
pii: 10.1186/s13046-024-03156-y
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Circulating MicroRNA
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
241Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2013;3(4):242–9. https://doi.org/10.3978/j.issn.2218-6751.2013.12.05 .
doi: 10.3978/j.issn.2218-6751.2013.12.05
Cho WCS, Tan KT, Ma VWS, et al. Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer. Oncotarget. 2018;9(91):36344–57. https://doi.org/10.18632/oncotarget.26349 .
doi: 10.18632/oncotarget.26349
pubmed: 30555633
pmcid: 6284742
Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013;19(22):6261–71. https://doi.org/10.1158/1078-0432.ccr-13-0596 .
doi: 10.1158/1078-0432.ccr-13-0596
pubmed: 24048333
Ulivi P, Petracci E, Marisi G, et al. Prognostic role of circulating miRNAs in early-stage non-small cell lung cancer. J Clin Med. 2019;8(2):131. https://doi.org/10.3390/jcm8020131 .
doi: 10.3390/jcm8020131
pubmed: 30678026
pmcid: 6407000
Kratz JR, Li JZ, Tsui J, et al. Genetic and immunologic features of recurrent stage I lung adenocarcinoma. Sci Rep. 2021;11(1):23690. https://doi.org/10.1038/s41598-021-02946-0 .
doi: 10.1038/s41598-021-02946-0
pubmed: 34880292
pmcid: 8654957
Qiu B, Guo W, Zhang F, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12(1):6770. https://doi.org/10.1038/s41467-021-27022-z .
doi: 10.1038/s41467-021-27022-z
pubmed: 34799585
pmcid: 8605017
Baverel PG, Dubois VFS, Jin CY, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631–42. https://doi.org/10.1002/cpt.982 .
doi: 10.1002/cpt.982
pubmed: 29243223
pmcid: 5887840
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009 .
doi: 10.1016/j.jtho.2015.09.009
pubmed: 26762738
Pasini L, Vannini I, Ulivi P, et al. Comparative analysis of free-circulating and vesicle-associated plasma microRNAs of healthy controls and early-stage lung cancer patients. Pharmaceutics. 2022;14(10):2029. https://doi.org/10.3390/pharmaceutics14102029 .
doi: 10.3390/pharmaceutics14102029
pubmed: 36297464
pmcid: 9610033
Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. https://doi.org/10.1002/jev2.12404 .
doi: 10.1002/jev2.12404
pubmed: 38326288
pmcid: 10850029
Simon RM, Subramanian J, Li MC, Menezes S. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform. 2011;12(3):203–14. https://doi.org/10.1093/bib/bbr001 .
doi: 10.1093/bib/bbr001
pubmed: 21324971
pmcid: 3105299
Chang L, Zhou G, Soufan O, Xia J. miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res. 2020;48(W1):gkaa467. https://doi.org/10.1093/nar/gkaa467 .
doi: 10.1093/nar/gkaa467
Shukuya T, Ghai V, Amann JM, et al. Circulating MicroRNAs and extracellular vesicle-containing MicroRNAs as response biomarkers of anti–programmed cell death protein 1 or programmed death-ligand 1 therapy in NSCLC. J Thorac Oncol. 2020;15(11):1773–81. https://doi.org/10.1016/j.jtho.2020.05.022 .
doi: 10.1016/j.jtho.2020.05.022
pubmed: 32565389
pmcid: 7641981
Kinoshita T, Yip KW, Spence T, Liu FF. MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet. 2017;62(1):67–74. https://doi.org/10.1038/jhg.2016.87 .
doi: 10.1038/jhg.2016.87
pubmed: 27383658
Bai X, He C, Fu B, et al. microRNA-877 contributes to decreased non-small cell lung cancer cell growth via the PI3K/AKT pathway by targeting tartrate resistant acid phosphatase 5 activity. Cell Cycle. 2020;19(23):3260–76. https://doi.org/10.1080/15384101.2020.1839697 .
doi: 10.1080/15384101.2020.1839697
pubmed: 33222607
pmcid: 7751652
Luo W, Sun C, Zhou J, et al. miR-135a-5p functions as a glioma proliferation suppressor by targeting tumor necrosis factor receptor-associated factor 5 and predicts patients’ prognosis. Am J Pathol. 2019;189(1):162–76. https://doi.org/10.1016/j.ajpath.2018.08.019 .
doi: 10.1016/j.ajpath.2018.08.019
pubmed: 30312580
Diao H, Xu X, Zhao B, Yang G. miR-135a-5p inhibits tumor invasion by targeting ANGPT2 in gallbladder cancer. Mol Med Rep. 2021;24(1):528. https://doi.org/10.3892/mmr.2021.12167 .
doi: 10.3892/mmr.2021.12167
pubmed: 34036386
pmcid: 8170269
Wang J, Yang J, Zhang H, Liao Y, Xu D, Ma S. Effects of miR-135a-5p and miR-141 on proliferation, invasion and apoptosis of colorectal cancer SW620 cells. Oncol Lett. 2020;20(1):914–20. https://doi.org/10.3892/ol.2020.11598 .
doi: 10.3892/ol.2020.11598
pubmed: 32566020
pmcid: 7286134
Jin X, Guan Y, Zhang Z, Wang H. Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer. BMC Cancer. 2020;20(1):329. https://doi.org/10.1186/s12885-020-06829-x .
doi: 10.1186/s12885-020-06829-x
pubmed: 32299382
pmcid: 7164187
Zhao H, Feng L, Cheng R, et al. miR-29c-3p acts as a tumor promoter by regulating β-catenin signaling through suppressing DNMT3A, TET1 and HBP1 in ovarian carcinoma. Cell Signal. 2024;113:110936. https://doi.org/10.1016/j.cellsig.2023.110936 .
doi: 10.1016/j.cellsig.2023.110936
pubmed: 37925048
Simiene J, Dabkeviciene D, Stanciute D, et al. Potential of miR-181a-5p and miR-630 as clinical biomarkers in NSCLC. BMC Cancer. 2023;23(1):857. https://doi.org/10.1186/s12885-023-11365-5 .
doi: 10.1186/s12885-023-11365-5
pubmed: 37697308
pmcid: 10496384
Gao S, Guo W, Liu T, et al. Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. Cancer Sci. 2022;113(2):648–59. https://doi.org/10.1111/cas.15222 .
doi: 10.1111/cas.15222
pubmed: 34837453
Jiang W, Zheng L, Yan Q, Chen L, Wang X. MiR-532-3p inhibits metastasis and proliferation of non-small cell lung cancer by targeting FOXP3. J BU : Off J Balk Union Oncol. 2019;24(6):2287–93.
Liu C, Lv D, Li M, et al. Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer. Int J Oncol. 2017;50(6):2079–90. https://doi.org/10.3892/ijo.2017.3967 .
doi: 10.3892/ijo.2017.3967
pubmed: 28440397
Kolenda T, Guglas K, Kopczyńska M, et al. Good or not good: role of miR-18a in cancer biology. Rep Pr Oncol Radiother. 2020;25(5):808–19. https://doi.org/10.1016/j.rpor.2020.07.006 .
doi: 10.1016/j.rpor.2020.07.006
Yang W, Yin Y, Bi L, et al. MiR-182-5p promotes the metastasis and epithelial-mesenchymal transition in non-small cell lung cancer by targeting EPAS1. J Cancer. 2021;12(23):7120–9. https://doi.org/10.7150/jca.60419 .
doi: 10.7150/jca.60419
pubmed: 34729113
pmcid: 8558643
Ghafouri-Fard S, Safarzadeh A, Katiraei SHF, Hussen BM, Hajiesmaeili M. Diverse functions of miR-328 in the carcinogenesis. Pathol - Res Pr. 2023;251:154896. https://doi.org/10.1016/j.prp.2023.154896 .
doi: 10.1016/j.prp.2023.154896
Trakunram K, Chaniad P, Geater SL, et al. Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer. Cancer Biol Med. 2020;17(3):652–63. https://doi.org/10.20892/j.issn.2095-3941.2020.0063 .
doi: 10.20892/j.issn.2095-3941.2020.0063
pubmed: 32944397
pmcid: 7476089
Zhou D, Ji G, Wei G, et al. MiR-361-3p promotes tumorigenesis of osteosarcoma cells via targeting ARID3A. Tissue Cell. 2022;76:101759. https://doi.org/10.1016/j.tice.2022.101759 .
doi: 10.1016/j.tice.2022.101759
pubmed: 35219069
Zhu K, Lin J, Chen S, Xu Q. miR-9-5p promotes lung adenocarcinoma cell proliferation, migration and invasion by targeting ID4. Technol Cancer Res Treat. 2021;20:15330338211048592. https://doi.org/10.1177/15330338211048592 .
doi: 10.1177/15330338211048592
pubmed: 34723712
pmcid: 8564129
Zou P, Zhu M, Lian C, et al. miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44. Sci Rep. 2019;9(1):19619. https://doi.org/10.1038/s41598-019-56018-5 .
doi: 10.1038/s41598-019-56018-5
pubmed: 31873114
pmcid: 6928221
Tang Z, Jiang Y, Ding S, Jiang S, Tang R, Luo P. miR-370 impacts the biological behavior of lung cancer cells by targeting the SMAD1 signaling pathway. Am J Transl Res. 2022;14(11):8117–28.
pubmed: 36505312
pmcid: 9730076
Zhang JX, Yang W, Wu JZ, et al. MicroRNA-32-5p inhibits epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting SMAD family 3. J Cancer. 2021;12(8):2258–67. https://doi.org/10.7150/jca.48387 .
doi: 10.7150/jca.48387
pubmed: 33758603
pmcid: 7974882
Ortiz-Quintero B. Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif. 2016;49(3):281–303. https://doi.org/10.1111/cpr.12262 .
doi: 10.1111/cpr.12262
pubmed: 27218664
pmcid: 6496612
Gayosso-Gómez LV, Ortiz-Quintero B. Circulating MicroRNAs in blood and other body fluids as biomarkers for diagnosis, prognosis, and therapy response in lung cancer. Diagnostics. 2021;11(3):421. https://doi.org/10.3390/diagnostics11030421 .
doi: 10.3390/diagnostics11030421
pubmed: 33801442
pmcid: 7999833
Wang D, Hao C, Zhang L, et al. Exosomal miR-125a-5p derived from silica-exposed macrophages induces fibroblast transdifferentiation. Ecotoxicol Environ Saf. 2020;192:110253. https://doi.org/10.1016/j.ecoenv.2020.110253 .
doi: 10.1016/j.ecoenv.2020.110253
pubmed: 32059163
Nicoloso MS, Sun H, Spizzo R, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010;70(7):2789–98. https://doi.org/10.1158/0008-5472.CAN-09-3541 .
doi: 10.1158/0008-5472.CAN-09-3541
pubmed: 20332227
pmcid: 2853025
Li B, Chen J, Wu Y, Luo H, Ke Y. Decrease of circARID1A retards glioblastoma invasion by modulating miR-370-3p/ TGFBR2 pathway. Int J Biol Sci. 2022;18(13):5123–35. https://doi.org/10.7150/ijbs.66673 .
doi: 10.7150/ijbs.66673
pubmed: 35982888
pmcid: 9379412
Wang S, Chen Y, Lei G, et al. Serum exosome-derived microRNA-193a-5p and miR-381-3p regulate adenosine 5’-Monophosphate-Activated Protein Kinase/Transforming Growth Factor Beta/Smad2/3 signaling pathway and promote fibrogenesis. Clin Transl Gastroenterol. 2024;15(2):e00662. https://doi.org/10.14309/ctg.000000000000066 .
doi: 10.14309/ctg.000000000000066
pubmed: 38099588
Ge L, Habiel DM, Hansbro PM, et al. miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways. JCI Insight. 2016;1(20):e90301. https://doi.org/10.1172/jci.insight.90301 .
doi: 10.1172/jci.insight.90301
pubmed: 27942594
pmcid: 5135276
Wang Y, Xue Q, Zheng Q, et al. SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. Lab Investig. 2021;101(4):463–76. https://doi.org/10.1038/s41374-020-00517-x .
doi: 10.1038/s41374-020-00517-x
pubmed: 33303972
Wei J, Yu H, Liu T, Wang Z, Lang C, Pan Y. FOXA1-induced LINC00621 promotes lung adenocarcinoma progression via activating the TGF-β signaling pathway. Thorac Cancer. 2023;14(21):2026–37. https://doi.org/10.1111/1759-7714.14986 .
doi: 10.1111/1759-7714.14986
pubmed: 37277890
pmcid: 10363846
Sato R, Imamura K, Semba T, et al. TGF-β signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma. Cancer Res. 2021;81(18):canres.3941.2020. https://doi.org/10.1158/0008-5472.can-20-3941 .
doi: 10.1158/0008-5472.can-20-3941
Qian C, Jiang Z, Zhou T, et al. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma. Front Immunol. 2022;13:1034992. https://doi.org/10.3389/fimmu.2022.1034992 .
doi: 10.3389/fimmu.2022.1034992
pubmed: 36524130
pmcid: 9745133
Cárdenas-Quesada N, Díaz-Beltrán L, Rosa-Garrido C, et al. TFG-β nuclear staining as a potential relapse risk factor in early-stage non-small-cell lung cancer. Int J Mol Sci. 2022;23(22):13780. https://doi.org/10.3390/ijms232213780 .
doi: 10.3390/ijms232213780
pubmed: 36430262
pmcid: 9694009
Lee JH, Shin KM, Lee SY, et al. Genetic variant of notch regulator DTX1 predicts survival after lung cancer surgery. Ann Surg Oncol. 2019;26(11):3756–64. https://doi.org/10.1245/s10434-019-07614-2 .
doi: 10.1245/s10434-019-07614-2
pubmed: 31313037
Vasileva MV, Khromova NV, Kopnin BP, Dugina VB, Kopnin PB. Significance of NOTCH1 expression in the progression of human lung and colorectal cancers. Biochem (Mosc). 2022;87(10):1199–205. https://doi.org/10.1134/s0006297922100133 .
doi: 10.1134/s0006297922100133
Sebastian NT, Webb A, Shilo K, et al. A PI3K gene expression signature predicts for recurrence in early-stage non–small cell lung cancer treated with stereotactic body radiation therapy. Cancer. 2023;129(24):3971–7. https://doi.org/10.1002/cncr.34983 .
doi: 10.1002/cncr.34983
pubmed: 37560930
Ye Q, Falatovich B, Singh S, Ivanov AV, Eubank TD, Guo NL. A multi-omics network of a seven-gene prognostic signature for non-small cell lung cancer. Int J Mol Sci. 2021;23(1):219. https://doi.org/10.3390/ijms23010219 .
doi: 10.3390/ijms23010219
pubmed: 35008645
pmcid: 8745553
Zhao J, Li X, Liu L, Zhu Z, He C. Exosomes in lung cancer metastasis, diagnosis, and immunologically relevant advances. Front Immunol. 2023;14:1326667. https://doi.org/10.3389/fimmu.2023.1326667 .
doi: 10.3389/fimmu.2023.1326667
pubmed: 38155975
pmcid: 10752943
Yu F, Liang M, Huang Y, Wu W, Zheng B, Chen C. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling. J Exp Clin Cancer Res. 2021;40(1):179. https://doi.org/10.1186/s13046-021-01979-7 .
doi: 10.1186/s13046-021-01979-7
pubmed: 34074322
pmcid: 8167983
Zhang X, Sai B, Wang F, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Mol Cancer. 2019;18(1):40. https://doi.org/10.1186/s12943-019-0959-5 .
doi: 10.1186/s12943-019-0959-5
pubmed: 30866952
pmcid: 6417285
Chang RM, Fu Y, Zeng J, Zhu XY, Gao Y. Cancer-derived exosomal miR-197-3p confers angiogenesis via targeting TIMP2/3 in lung adenocarcinoma metastasis. Cell Death Dis. 2022;13(12):1032. https://doi.org/10.1038/s41419-022-05420-5 .
doi: 10.1038/s41419-022-05420-5
pubmed: 36494333
pmcid: 9734149
Hsu YL, Hung JY, Chang WA, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017;36(34):4929–42. https://doi.org/10.1038/onc.2017.105 .
doi: 10.1038/onc.2017.105
pubmed: 28436951
Luo C, Xin H, Zhou Z, et al. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression. Hepatology. 2022;76(4):982–99. https://doi.org/10.1002/hep.32387 .
doi: 10.1002/hep.32387
pubmed: 35106794
Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414-427.e13. https://doi.org/10.1016/j.cell.2019.02.016 .
doi: 10.1016/j.cell.2019.02.016
pubmed: 30951669
pmcid: 6499401
Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of extracellular vesicles. Biomed Res Int. 2018;2018:8545347. https://doi.org/10.1155/2018/8545347 .
doi: 10.1155/2018/8545347
pubmed: 29662902
pmcid: 5831698